title: FDA new drug approvals in 2010.
authors: Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, MD, USA.
authors: Richard L
authors: RL
authors: Wynn
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D058833:Antithrombin Proteins / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use; D017277:Drug Approval; D004387:Dupuytren Contracture / Q000188:drug therapy; D005776:Gaucher Disease / Q000188:drug therapy; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000627:therapeutic use; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D000982:Antipruritics; D014150:Antipsychotic Agents; D018501:Antirheumatic Agents; D058833:Antithrombin Proteins; D050071:Bone Density Conservation Agents; D003276:Contraceptives, Oral; D006074:Gout Suppressants; D007004:Hypoglycemic Agents; D009465:Neuromuscular Agents; D026902:Potassium Channel Blockers; D012597:Sclerosing Solutions